- Home
- KROS vs SRV Comparison
KROS vs SRV Comparison
Compare KROS & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | SRV |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 225.9M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | KROS | SRV |
|---|---|---|
| Price | $10.68 | $46.00 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $21.86 | N/A |
| AVG Volume (30 Days) | ★ 189.2K | 73.8K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $243,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,751.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.69 | $38.11 |
| 52 Week High | $22.55 | $51.54 |
Technical Indicators
Market Signals| Indicator | KROS | SRV |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 40.55 |
| Support Level | $10.57 | $43.83 |
| Resistance Level | $11.55 | $46.19 |
| Average True Range (ATR) | 0.50 | 1.29 |
| MACD | 0.08 | -0.15 |
| Stochastic Oscillator | 63.06 | 30.43 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end investment company. Its investment objective is to obtain a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in a portfolio of midstream energy investments.